The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial
Recruiting
Phase 3
Interventional Study
Endometriosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 110 (estimated)
- Sponsor
- Main Line Health · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this investigator-initiated single-site clinical trial is to compare the overall quality of life of participants taking Relugolix combination therapy (Rel-CT) following excisional surgery for endometriosis to participants that do not take Rel-CT following the same surgery. Rel-CT is an FDA approved form of medical treatment for endometriosis. It is known to work in treating endometrios…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
* Age ≥ 18 years
* Planning to undergo an elective laparoscopic or robotic procedure for known or suspected endometriosis
Exclusion criteria
-A known contraindication to REL-CT. Contraindications include:
* High risk of arterial, venous thrombotic, or thromboembolic disorder
*…
Contacts